

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2

Revision Date: 06.04.2024

SDS Number: 42891-00026

Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Section 1: Identification

Product name : Insulin Glargine Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification

GHS Classification

Acute toxicity (Inhalation) : Category 4

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Nervous system)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.
H318 Causes serious eye damage.
H332 Harmful if inhaled.
H373 May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2	Revision Date: 06.04.2024	SDS Number: 42891-00026	Date of last issue: 30.09.2023 Date of first issue: 07.01.2015
----------------	------------------------------	----------------------------	---

Precautionary statements

: **Prevention:**

P261 Avoid breathing dust.
P264 Wash skin thoroughly after handling.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ eye protection/ face protection.

: **Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
P314 Get medical advice/ attention if you feel unwell.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

: **Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Insulin Glargine	160337-95-1	>= 90 -<= 100
m-Cresol	108-39-4	>= 3 -< 5

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

In case of eye contact	Thoroughly clean shoes before reuse. : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes skin irritation. Causes serious eye damage. Harmful if inhaled. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2	Revision Date: 06.04.2024	SDS Number: 42891-00026	Date of last issue: 30.09.2023 Date of first issue: 07.01.2015
----------------	------------------------------	----------------------------	---

cannot be contained.

Methods and materials for containment and cleaning up

- : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
Conditions for safe storage	: Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023 Date of first issue: 07.01.2015

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Insulin Glargine	160337-95-1	TWA	3 µg/m3 (OEB 4)	Internal
m-Cresol	108-39-4	WES-TWA (Inhalable Fraction and Vapour)	1 ppm 4.5 mg/m3	NZ OEL
Further information: Skin absorption				
		TWA (Inhalable fraction and vapor)	20 mg/m3	ACGIH

Engineering measures

- Ensure adequate ventilation, especially in confined areas.
- Minimize workplace exposure concentrations.
- Apply measures to prevent dust explosions.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection : Chemical-resistant gloves

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment: Chemical resistant goggles must be worn.
If splashes are likely to occur, wear:
Face-shield

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Section 9: Physical and chemical properties

Appearance	:	Crystalline powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 12.5 mg/l
Exposure time: 4 h
Test atmosphere: vapour
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Insulin Glargine:

Acute oral toxicity : Remarks: No data available

Acute inhalation toxicity : Remarks: No data available

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Acute dermal toxicity : Remarks: No data available

m-Cresol:

Acute oral toxicity : LD50 (Rat): 121 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : Acute toxicity estimate: 0.5001 mg/l
Exposure time: 4 h
Test atmosphere: vapour
Method: Expert judgement
Remarks: Based on national or regional regulation.

Acute dermal toxicity : LD50 (Rabbit): 301 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes skin irritation.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit
Result : Corrosive after 3 minutes to 1 hour of exposure

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit
Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Components:

Insulin Glargine:

Remarks : No data available

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

Insulin Glargine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

m-Cresol:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 475
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Insulin Glargine:

Species : Rat
Exposure time : 2 Years
NOAEL : 0.455 mg/kg body weight
Result : negative

Insulin Glargine FormulationVersion
7.2Revision Date:
06.04.2024SDS Number:
42891-00026Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Species : Mouse
Exposure time : 2 Years
NOAEL : 0.455 mg/kg body weight
Result : negative

m-Cresol:

Species : Mouse, males
Application Route : Ingestion
Exposure time : 105 weeks
Result : equivocal
Remarks : Based on data from similar materials

Species : Mouse, female
Application Route : Ingestion
Exposure time : 106 - 107 weeks
Result : positive
Remarks : Based on data from similar materials

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

Reproductive toxicity

Not classified based on available information.

Components:**Insulin Glargine:**

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.36 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Subcutaneous
Fertility: NOAEL: 0.072 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: NOAEL: 0.36 mg/kg body weight
Result: No effects on foetal development

Species: Rabbit
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0.072 mg/kg body weight
Result: Fetotoxicity
Remarks: The mechanism or mode of action may not be rele-

SAFETY DATA SHEET



Insulin Glargine Formulation

Version
7.2

Revision Date:
06.04.2024

SDS Number:
42891-00026

Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

vant in humans.

m-Cresol:

Effects on fertility

: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development

: Test Type: Prenatal development toxicity study (teratogenicity)
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information.

Components:

m-Cresol:

Assessment

: May cause respiratory irritation.

Remarks

: Based on national or regional regulation.

STOT - repeated exposure

May cause damage to organs (Blood, Nervous system) through prolonged or repeated exposure if swallowed.

Components:

Insulin Glargine:

Exposure routes

: Ingestion

Target Organs

: Blood, Nervous system

Assessment

: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Insulin Glargine:

Species

: Rat

NOAEL

: 0.5 mg/kg

LOAEL

: 1.5 mg/kg

Application Route

: Subcutaneous

Exposure time

: 30 d

Target Organs

: Blood, Nervous system

m-Cresol:

Species

: Rat

NOAEL

: 150 mg/kg

Application Route

: Ingestion

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Exposure time : 13 Weeks
Method : OECD Test Guideline 408

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Insulin Glargine:

Inhalation : Target Organs: Blood
Symptoms: Hypoglycemia, Headache, Sweating, Tremors, Nausea

Section 12: Ecological information

Ecotoxicity

Components:

m-Cresol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 8.6 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia pulex (Water flea)): > 99.5 mg/l
Exposure time: 48 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1.35 mg/l
Exposure time: 32 d
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1 mg/l
Exposure time: 21 d
Remarks: Based on data from similar materials

Persistence and degradability

Components:

m-Cresol:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 90 %
Exposure time: 28 d
Method: OECD Test Guideline 301D

Bioaccumulative potential

Components:

m-Cresol:

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

Bioaccumulation : Species: Leuciscus idus (Golden orfe)
Bioconcentration factor (BCF): 17 - 20

Partition coefficient: n-octanol/water : log Pow: 1.96

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2 Revision Date: 06.04.2024 SDS Number: 42891-00026 Date of last issue: 30.09.2023
Date of first issue: 07.01.2015

EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

not allocated

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Revision Date : 06.04.2024

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

SAFETY DATA SHEET



Insulin Glargine Formulation

Version 7.2	Revision Date: 06.04.2024	SDS Number: 42891-00026	Date of last issue: 30.09.2023 Date of first issue: 07.01.2015
----------------	------------------------------	----------------------------	---

ACGIH NZ OEL	: USA. ACGIH Threshold Limit Values (TLV) : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants
ACGIH / TWA NZ OEL / WES-TWA	: 8-hour, time-weighted average : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN